FRAXA Research Foundation’s Post

It was an absolute pleasure to co-chair the Novel Technologies Workgroup at the invitation of Crohn's & Colitis Foundation for the new, 2024 version of Challenges in IBD. This was a year-long process and many colleagues, across disciplines have contributed. I am grateful to colleagues with expertise in clinical IBD, as well as engineering and science. We have identified 3 main gaps, that we think are addressable by novel technologies, over the next 5 years. First gap is in the diagnostic realm, where we believe that novel technologies can provide with earlier, more precise diagnostics. The second gap is in novel therapeutics - either targeted, or sustained release, or more precise. The third gap is in the collaboration among stakeholders - including clinicians, scientists, engineers and patients. We offer potential solutions, and hope this document will serve as a roadmap for both scientific endeavors, as well as funding decisions, over the next 5 years. Special thanks to Alan Moss, Andres Hurtado-Lorenzo, PhD, Russell Wyborski and Nicole MJ Schwerbrock! https://lnkd.in/d2JQXAEH

Proteios has been selected as a member of CASA-Bio (Catalyzing Across Sectors to Advance the Bioeconomy) to advance biotechnology and biomanufacturing through foundational and use-inspired research and development.  CASA-Bio was created on September 2022 by Executive Order (EO) on “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy.”  Proteios is participating under the “Human Health” EO Bioeconomy theme with our novel multidimensional cell isolation technology to provide clinicians with unprecedented access to immune cell subpopulations and precise control of cell therapy compositions.  Cell therapies, especially in cancer treatment like CAR-T cell therapies, present a vast untapped potential but face significant challenges in basic science, cell sourcing, manufacturing, and in vivo performance control.  Proteios looks forward to addressing these challenges to improve the range of conditions for which cell therapies can be routinely applied.

Meet Amelie Eriksson Karlström, Professor of Molecular Biotechnology at KTH! Amelie's research focuses on protein engineering, affinity technologies, and bioconjugation chemistry. Her team is developing innovative technologies for diagnostic and therapeutic applications, with a special emphasis on targeted radionuclide therapy for cancer. "I like to learn new things and I am motivated by unexpected findings. I also really like designing and building molecules." She highlights antibody therapies as a key breakthrough impacting her work, especially in the development of antibody-drug conjugates and radioimmunoconjugates. "New biotechnological methods will make it possible to develop therapies that are more efficient and have fewer side effects than today’s drugs. This will make treatments more accessible to a larger patient population." #LifeScience #Biotechnology #Research #GlobalHealth #KTH

🚀 We are excited to announce that our latest study on developing a predictive model for the efficacy of BCL2 inhibitors by profiling the BCL2 protein family has been published in Nature Biomedical Engineering. 💡 The research highlights the potential of single-molecule pull-down and co-immunoprecipitation (SMPC) for extensive and accurate protein complex profiling, paving the way for precision medicine in therapies targeting protein complexes. While cutting-edge technologies like single-protein sequencing primarily serve as discovery tools, our showcased technique is a game-changer. It's specifically designed for examining dozens of protein complexes in clinical specimens. These detailed profiles can be seamlessly integrated to provide crucial insights into drug efficacies, significantly streamlining treatment decisions that would be challenging to achieve through genomic and proteomic profiling alone. In ongoing collaboration with leading scientists at Seoul National University and Seoul National Hospital, we have reached another milestone, emphasizing the crucial role of PPI analysis in evaluating patient dependencies on targeted anti-cancer drugs.   Please check out the link below to access the full paper: https://lnkd.in/gGWmjhhp #PrecisionMedicine #Biotech #Innovation #ProteinComplexes #CancerResearch #AML #DrugDiscovery #Proteina #NatureBiomedicalEngineering

🚀 Join us on March 12, 2024, from 5 PM (GMT) onward, for our showcase event in Oxford: "Immunopeptidomics in Drug Discovery." Immerse yourself in captivating presentations from our collaborators Grey Wolf Therapeutics and Immunocore. Connect with fellow enthusiasts, engage in in-depth discussions, and explore the profound impact of Biognosys' technology on groundbreaking research. 🌐 Sneak peek into the agenda: "First-in-class inhibitors of ERAP1 generate novel targets for MHCI-directed therapeutics" by Dr. Wayne Paes, Cancer Immunologist at Grey Wolf Therapeutics "Identifying targets for immunotherapy with large scale immunopeptidomics" by Dr. Ricardo J. Carreira, Associate Director Proteomics at Immunocore 🚪 Biognosys will also showcase poster presentations, including "HLA Class I and II neoantigen mapping in MSI-high colorectal cancer biopsies" (in collaboration with Indivumed Therapeutics) and more from Oxbridge Biotechs. 🥂 Stick around for the Social Mixer afterward, where you can connect with drug development and proteomics experts over cold beverages and snacks. We're eager to have you join us for this enlightening event. Register here: https://lnkd.in/ekaJWbhs ✨ #Immonotherapy #ImmunoOncology #DrugDevelopment #DrugDiscovery #Biomarkers #Immunopeptidomics

Last week was full of exciting news in the biotech industry! -Illumina's NovaSeq 6000 is making waves in spatial transcriptomics - Bluejay raised $182 million to advance treatments for viral liver conditions. - Vizgen celebrated a legal victory and expanded their antitrust case against 10x Genomics and Harvard. - Akoya Biosciences and NeraCare are collaborating to develop melanoma tests. - Immunology and inflammatory-focused biotechs are also seeing significant interest, with Attovia closing a $105 million series B to advance their pipeline of biologics. - NanoString Technologies and Bruker also had a big win as a patent was invalidated in the German Federal Patent Court. - Seer is expanding accessibility to proteomic solutions with a new Technology Access Center in Europe. Exciting times in the biotech industry! #biotech #innovation #science

Non-dilutive #governmentfunding webinar is TODAY, Jan 18 @ 12pm ET. Hear from experts on #government #grants for #health innovators #lifesciences #biotech #therapeutics #medicaldevices #diagnostics #digitalhealth and more! See link below.

🌟 Exciting News in Drug Discovery! 🌟 Thrilled to share the publication of groundbreaking research titled "A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models" in Nature Biotechnology by Alex Zhavoronkov and the team at Insilico Medicine! 🔬 Leveraging cutting-edge AI technology, Alex Zhavoronkov and the Insilico Medicine team identified and TNIK as a promising anti-fibrotic target, paving the way for innovative therapeutic interventions. Key highlights: 1️⃣ Utilization of AI to discover TNIK as an anti-fibrotic target. 2️⃣ "Hallmarks of aging assessment" revealed promising results for TNIK. 3️⃣ Innovative molecule design using Chemistry42 AI for enhanced safety and efficacy. 4️⃣ Extensive in vitro and in vivo experiments leading preclinical candidates for lung and kidney fibrosis. 5️⃣ Successful completion of a clinical safety trial in humans. Excitingly, the paper is easily accessible for questions through the chat feature at https://lnkd.in/gzm3FaMW, and a comprehensive data repository is available at https://lnkd.in/gudR2pZN. 🌐 Explore recent publications and collaborations by Alex and Insilico, and dive into the therapeutic pipeline propelled by generative platforms. Read the full paper here: https://lnkd.in/epYVmPgf #Biotechnology #Innovation #AI #FibrosisResearch #TherapeuticDevelopment #NatureBiotechnology #ResearchBreakthroughs

🔬 As molecular diagnostics and drug discovery progresses forward, the role of biobanks will only increase, making them an essential component in biomedical research. 📑 In this article, we explained the role of biobanking in preclinical research, explored the hurdles researchers are currently facing, and potential solutions on the horizon that could mitigate these challenges. ➡ Read the full article here - https://lnkd.in/gU5nu6kw

🚀 Exciting news from Opal Therapeutics! They have been awarded $275,000 by the National Science Foundation (NSF) for their groundbreaking work in AI-driven PROTAC drug discovery. This project aims to develop non-hormonal therapeutic targets for uterine fibroids and endometriosis, conditions that affect millions of women worldwide. By focusing exclusively on female biology, Opal Therapeutics is set to revolutionize treatment options and improve the quality of life for many. #SBIR #STTR #Innovation #Healthcare 🔬 The award, part of the Small Business Innovation Research Program Phase I, will last for 12 months, starting from September 1, 2024, to August 31, 2025. This initiative will utilize patient-derived uterine organoids and AI algorithms to identify disease-relevant phenotypes and propose new therapeutic solutions. Kudos to Opal Therapeutics for their dedication to women's health! #Research #AI #Biotech #WomenInScience